HIV·HCV coinfection

HIV/HCV coinfection is the concurrent infection with human immunodeficiency virus and hepatitis C virus. It is especially important because the two viruses share transmission routes and can compound one another’s effects: HIV accelerates HCV-related liver injury, while HCV may influence renal disease and, in some studies, HIV progression. The condition therefore belongs simultaneously to hepatology, infectious disease, nephrology, and treatment decision-making rather than to a single-organ disease model.

Epidemiology and Transmission

HIV/HCV coinfection is common among people living with HIV, with an estimated prevalence of approximately 30%, although reported rates range from below 10% to above 70%. The variation largely reflects the patient’s risk profile. People who acquired HIV through illicit intravenous drug use or unsafe and promiscuous sex have the highest rates of HCV coinfection, whereas patients infected with HIV through other routes generally have lower rates.

The sequence of infection can also differ by transmission setting. Intravenous drug users typically acquire HCV before HIV, while men who have sex with men more commonly acquire HIV before HCV. These patterns reflect overlapping but not identical transmission networks and help explain why coinfection is distributed unevenly across patient populations.

The broader history of HCV transmission also matters in patients with chronic kidney disease and those receiving hemodialysis. Once HCV was recognized as the major cause of non-A non-B hepatitis, hemodialysis patients were identified as a high-risk group because of transfusion exposure and nosocomial transmission within dialysis units. Molecular studies later confirmed transmission clusters among patients treated in the same units, while investigations generally implicated failures in infection-control procedures rather than the internal pathway of the dialysis machine. Thus, coinfection may arise within the same wider exposure environments that affect other vulnerable medical populations.

Interaction with Liver Disease and HIV Progression

HIV has a distinctly adverse effect on the course of HCV-related liver disease. Coinfection accelerates fibrosis and increases morbidity and mortality from HCV-induced liver disease. The proposed mechanisms include the immunosuppressive effect of HIV and increased production of pro-inflammatory cytokines, which together promote a more rapid progression toward end-stage liver failure.

The complications are not limited to the rate of fibrosis. Some evidence suggests that hepatocellular carcinoma develops at a younger age in coinfected patients and carries a worse prognosis than in patients with HCV infection alone. This makes the distinction between active and resolved HCV infection clinically important: chronic infection is established by both anti-HCV positivity and detectable HCV RNA, while antibody positivity alone cannot distinguish ongoing infection from recovery.

Antiretroviral therapy has a beneficial effect on the progression of liver disease and is therefore central to management. Its use is not without difficulty, however, because chronic HCV-related liver disease can increase the hepatotoxicity of some antiretroviral agents. Treatment requires a balance between suppressing HIV, protecting the liver, and avoiding medication-related injury.

The influence of HCV on HIV itself is less settled. Some studies have suggested that HCV worsens progression to a new AIDS-defining illness or death, while others have not reproduced those findings. HCV viral load may account for part of the disagreement, since a clear correlation has been reported between HCV viral load and the risk of progression to AIDS and death in HIV-infected patients. The evidence therefore supports concern about an adverse interaction without establishing a uniform effect in every patient.

Renal Manifestations

HIV/HCV coinfection is particularly complex when kidney disease is present. Both viruses can produce renal complications, and patients with coinfection may develop several immune-complex glomerular diseases in addition to the classical HIV-associated nephropathy. Reported lesions include membranoproliferative glomerulonephritis, immunoglobulin A nephropathy, non-collapsing focal segmental glomerulosclerosis, membranous nephropathy, and lupus-like glomerulonephritis.

HCV-associated cryoglobulinemic membranoproliferative glomerulonephritis is the characteristic HCV-related renal lesion. Its systemic setting may include purpura, arthralgias, Raynaud phenomena, skin necrosis, or pulmonary hemorrhage, together with hypocomplementemia, increased rheumatoid factor, and circulating type II cryoglobulins. Renal pathology may show mesangial proliferation, double-contour capillary walls, immunoglobulin G, immunoglobulin M, and complement C3 deposits, subendothelial electron-dense deposits, cryoglobulin thrombi obstructing capillary lumens, and occasional vasculitis of extraglomerular vessels.

Clinical presentation ranges widely. Some patients have persistent non-nephrotic proteinuria and microscopic hematuria with preserved renal function; others develop nephrotic syndrome, visible hematuria, and acute renal failure. More generally, HCV-associated mixed cryoglobulinemia can produce proteinuria, hematuria, reduced estimated glomerular filtration rate, acute nephritic syndrome, or nephrotic syndrome. Purpura, arthralgias, and neuropathy may precede kidney disease by several years, and liver enzyme abnormalities may be absent or only mild.

The specific contribution of HCV to renal disease in HIV-infected patients remains difficult to determine. Many patients with membranoproliferative lesions have circulating cryoglobulins, allowing their disease to be interpreted as HCV-related cryoglobulinemic glomerulonephritis, but systemic manifestations of cryoglobulinemia appear less common in coinfected patients than in patients without HIV. HCV may also contribute to immune-complex diseases other than membranoproliferative glomerulonephritis, although the available clinical and investigative evidence is limited.

Coinfection may have consequences even without overt glomerular disease. In a study of HIV-infected women, HCV seropositivity was independently associated with a more rapid decline in renal function among those who already had chronic kidney disease, defined by an estimated glomerular filtration rate below 60 ml/min/1.73 m2. The association was not observed among participants with normal renal function. This contrast suggests that HCV may act as an additional accelerator once renal reserve is already reduced rather than as a uniform cause of decline in every HIV-infected patient.

Prognosis and Treatment Implications

The prognosis of glomerular disease in HIV/HCV coinfection has historically been poor, with very low patient and renal survival in reported series. In one follow-up experience, no patient received specific HCV therapy; most received renin-angiotensin system blockers, nearly nine-tenths received antiretroviral therapy, and a minority received corticosteroids at presentation. Three patients died, eight progressed to chronic dialysis, and renal function remained stable in sixteen patients. These outcomes illustrate both the severity of the disease and the heterogeneity of its course.

The prognosis appeared better in the series in which most patients received antiretroviral therapy than in earlier reports, many of which predated widespread antiretroviral treatment. On that basis, antiretroviral therapy should be prescribed for HIV-infected patients with glomerular disease regardless of whether they are also infected with HCV. The experience with HIV-associated nephropathy supports this approach, while the evidence for other glomerular lesions remains more limited.

HCV treatment is more difficult to assess in the coinfected renal population because published recommendations and studies have traditionally focused on HCV-induced liver disease rather than kidney outcomes. For chronic HCV infection generally, evaluation should include both hepatic and extrahepatic effects, including cryoglobulinemia-associated vasculitis. Liver assessment can use biopsy or noninvasive methods such as FibroScan, and active infection requires detectable HCV RNA rather than antibody positivity alone.

The antiviral landscape has also changed. Pegylated interferon and ribavirin therapy produced sustained virologic response in more than half of patients with chronic HCV infection, although more than half of those with genotype 1 failed to achieve that endpoint. Direct-acting antiviral drugs, including protease and polymerase inhibitors, were developed to target specific stages of the HCV life cycle; early triple regimens with telaprevir or boceprevir increased sustained virologic response rates in genotype 1 infection. In coinfected patients, however, treatment must account for renal status, liver injury, antiretroviral interactions, toxicity, and adherence.

Clinical Significance and Remaining Uncertainty

HIV/HCV coinfection demonstrates how one infection can alter the natural history, classification, and treatment of another. HIV can intensify HCV fibrosis and liver failure, while HCV may worsen outcomes in patients with established chronic kidney disease and may be associated with HIV progression in some populations. At the same time, the renal pathology cannot always be assigned cleanly to one virus, because HIV-associated and HCV-associated immune-complex diseases overlap and may coexist.

The concept therefore requires careful separation of infection status, active viral replication, organ injury, and causation. Anti-HCV antibodies identify exposure, but HCV RNA identifies active infection. Cryoglobulins and renal biopsy can clarify an HCV-associated vasculitic process, while the presence of HIV-associated nephropathy or another immune-complex lesion may point to a different or mixed mechanism. The scarcity of coinfection-specific renal studies leaves important questions unresolved, but the available evidence consistently supports integrated care: antiretroviral therapy, structured assessment of HCV activity and liver fibrosis, attention to cryoglobulinemic renal disease, and cautious selection of antiviral therapy.